Zydus Cadila Gets USFDA Nod For Generic Antiviral Drug, Atazanavir Capsules
Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Atazanavir capsules, an antiviral drug, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Atazanavir capsules in strengths of 150 mg, 200 mg and 300 mg, Zydus Cadila said in a statement.
Atazanavir, an antiretroviral drug, is used to treat Human Immunodeficiency Virus (HIV-1) infection incombination with other antiretroviral drugs.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The Zydus Group now has 291 approvals and has so far filed over 390 abbreviated new drug application (ANDAs) since the commencement of the filing process in 2003-04, the company said.
Coutts Sets Scope On New Continent
Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more
From Cypherpunk To Citadel
How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more
ACB Securities: Building Scale, Trust & Innovation
ACB Securities: Building Scale, Trust and Innovation in Vietnam’s Capital MarketsACB Securities (ACBS) is emerging as ... Read more
War Risk Returns To Markets As VIX Surges
For most of the past year, global markets behaved as though geopolitical risk had largely disappeared. Inflation was eas... Read more
Stablecoin The Future Of Currency?
The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more
BoE Loosens Capital Rules
The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more